Background: Development and progression of cancer is accompanied by different morphological and functional changes of cells. One of the most important changes is the expression and activity of enzymes in the cellular fatty acids metabolism that reflects in cell membrane lipid composition and increases fluidity of cancer cell membrane. The Ellipin, prepared from bovine liver, is a newly developed anticancer agent containing several important fatty acids.Goal: To investigate effects of Ellipin on hepatic cancer cell function such as proliferation, migration and adherent activity and apoptosis of cancer cell lines in vitro.Materials and Methods: This study was conducted in the Laboratory of Molecular Biology, Institute of Biology, MAS. The Ellipin was developed in the Drug Research Institute of Monos group. HepG2, HCC, 23132/87, MDCK cells lines and the primary liver cancer cells (PCC) were used for proliferation assay. Only HepG2 cell line was used for MTT, Migration, Spreading and Apoptosis assays.Results: The results of proliferation assay showed that the ellipin decreased the proliferation activity of HepG2 and PCC cells depending on concentrations; in 50μg/ml 2-3 times, 250μg/ml fully stopped cells divisions. The Ellipin reduced mitochondrial reeducates enzyme activity of HepG2 cells depending on its concentrations. For example, in 50μg/ml ellipin concentration case, the number of alive cells decreased 2 times. The migration of HepG2 cells treated with 100μg/ml ellipin was decreased by 22.3% compared to the control cells. Also the number of adhered cells was reduced by Ellipin treatment. After 50μg/ml, 100μg/ml, 250μg/ml ellipin treatment, the number of apoptic cells were 14,6%, 45,6%, 100% of initial culture cells, respectively.Conclusions: Our results showed that the Ellipin suppresses HepG2 cancer cell proliferation and decreases migration and spreading activities and also inducts the cell apoptosis.

Atherogenic dyslipidemia comprises a triad of increased blood concentrations of small, dense low density lipoprotein (LDL) particles, decreased high-density lipoprotein (HDL) particles, and increased triglycerides. A typical feature of obesity, the metabolic syndrome, atherogenic dyslipidemia has emerged as an important risk factor for cardiovascular disease. We have determined levels of serum lipid profiles in 1861 older people who lives 5 regions in Mongolia. The concentrations of total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) were measured using a biochemical reagents by biochemical fully automated analyzer. The levels of LDL-C were calculated by the Friedewald equation. Overall prevalence of dyslipidemia was 4.3% in men and 3.0% in women. Logistic regression showed that Odds ratio of the atherogenic dyslipidemia was OR=1.3, p=0.001 (CI 95% 0.93-2.47) for body mass index, OR=1.6, p=0.02 (CI 95% 1.0-2.88) for waist circumference, OR=1.76, p=0.03 (CI 95% 1.12-3.54) for waist hip ratio. Odds ratio of the atherogenic dyslipidemia was OR=0.98, p=0.001 (CI 95% 0.34-1.05) for gender and OR=1.0 p=0.001 (CI 95% 0.65-1.03) for age. Overall, 3.3% of older people had atherogenic dyslipidemia and 4.3% of men and 3.0% of women had atherogenic dyslipidemia. An increase of physical parameters are getting a risk factor of atherogenic dyslipidemia.